Introduction: Are We Missing the Most Important Piece? Over the past few years, mRNA therapeutics has rapidly expanded—from vaccines to cancer immunotherapy, gene editing, and protein replacement. But if you’ve actually worked in this space, you’ve probably had this intuition: Often, it’s not that your design isn’t good enough—it’s that delivery just doesn’t work. So we optimize: Codon usage Nucleoside modifications Cap and poly(A) tail LNP formulations All of these matter. B

Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottl

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Introduction Messenger RNA (mRNA) has redefined what is possible in modern medicine. As a therapeutic platform, it enables rapid vaccine development, personalized cancer immunotherapy, and protein replacement strategies for rare diseases. However, behind every successful mRNA therapeutic lies a carefully engineered synthesis process. While clinical outcomes often dominate the conversation around mRNA therapeutics, the quality of mRNA synthesis ultimately determines translatio